Blood Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Lipid Research
Trial data on hyperlipidemia drug mevalotin show artery disease significantly suppressed
December 29th, 2005
Daichi Sankyo Company, Limited presented the results of the large scale clinical trial MEGA Study employing mevalotin, which indicated that onset of coronary artery disease was significantly suppressed by 33% (p=.010). In particular, the onset of myocardial infarction was significantly suppressed by 48% (p=.03). Results were presented at the annual American Heart Association (AHA) 2005 Scientific Sessions held in Dallas, Texas. The generic name of the cholesterol-lowering compound mevalotin is pravastatin sodium. This was a special study initiated in 1993 as a contract research project sponsored by the Ministry of Health, Labor and Welfare (the...
Source: Blood Weekly (2005-12-29)
|
